Previous Next Index Thread
Previous Next Index Thread
AIDS Daily Summary
June 28, 1996
The Centers for Disease Control and Prevention (CDC) National
AIDS Clearinghouse makes available the following information as a
public service only. Providing this information does not
constitute endorsement by the CDC, the CDC National AIDS
Clearinghouse, or any other organization. Reproduction of this
text is encouraged; however, copies may not be sold, and the CDC
National AIDS Clearinghouse should be cited as the source of this
information. Copyright 1996, Information, Inc., Bethesda, MD
******************************************************
"AMA Backs Mandatory HIV Testing of Pregnant Women and Newborns"
"FDA Clears Drug to Treat Blindness in AIDS Patients"
"New Blood Treatment May Help Fight AIDS"
"Doctors Discover New Worm, One That's Lethal to Humans"
"HIV Infections on the Rise in Japan"
"STD Expert Says CDC's Gonorrhea Guidelines Are Outdated"
"Restricted Expression of KS-Associated HHV8 Found in KS Tissue"
"Bacterial Infections Associated With HIV-Related Oral Lesions"
"Test Case"
"Public Spending on AIDS"
******************************************************
"AMA Backs Mandatory HIV Testing of Pregnant Women and Newborns"
Washington Post (06/28/96) P. A2
In a surprising reversal on a controversial issue, the
American Medical Association announced Thursday the
organization's endorsement of mandatory HIV testing for all
pregnant women and newborns. The group had advocated voluntary
testing because doctors did not have the tools to treat pregnant
women with HIV. This changed, however, with the discovery that
AZT can markedly reduce the risk of transmitting the virus to the
child. Opponents to mandatory testing, including AIDS activists,
civil libertarians, and some mothers, argued that testing would
lead to discrimination. Many doctors also argued that mandatory
testing would drive the women most at risk away from medical
care. The AMA's decision does not carry legal weight, but the
group's policies do influence lawmakers.
"FDA Clears Drug to Treat Blindness in AIDS Patients"
Wall Street Journal (06/28/96) P. B3
The Food and Drug Administration has approved Gilead
Sciences' drug Vistide as a treatment for cytomegalovirus, a
virus that causes blindness in AIDS patients. The drug is
Gilead's first commercial product. Analysts have predicted that
the approval could lead to approximately $45 million of sales
over the next year. Gilead, which has been investing heavily in
research and development, had a net loss of $10.8 million, or 42
cents a share, on sales of $779,000 in the first quarter. The
company's stock rose 75 cents, to $23.75, in Nasdaq Stock Market
trading.
"New Blood Treatment May Help Fight AIDS"
Washington Times (06/28/96) P. A3
Researchers at the Naval Medical Research Center reported
Thursday that a new preliminary experiment has allowed them to
produce a large number of immune cells that seem to resist HIV in
the laboratory. Carl June and colleagues report their results in